卫信康(603676) - 卫信康投资者关系活动记录表（2024-03-29）

Group 1: Company Overview - The company is Tibet Weixin Kang Pharmaceutical Co., Ltd. with stock code 603676 [1][2] - The investor relations activity took place on March 1, 2024, in Beijing, Chengdu, and Xiamen [2][3] Group 2: Sales and Market Performance - As of now, 14 provinces have officially executed the results of the alliance procurement, with 5 more provinces expected to follow in the coming months [3][4] - The company has developed over 370 hospitals for its pediatric multivitamin injection since March 1, 2023, with continuous growth in hospital coverage [3][4] - The sales of the compound electrolyte injection (V) have shown a stable market demand, with over 20 hospitals developed by the end of last year [4] Group 3: Financial Performance and Shareholder Returns - The company has maintained a cash dividend ratio exceeding 30% of the net profit attributable to shareholders since its listing, with the past three years showing a dividend ratio over 50% [4] - The company is exploring the feasibility of multiple dividends within a year, ensuring it does not affect its operational capabilities or shareholder interests [4]